Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis

• Status: Unknown status
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Cytokines such as such as TNF-a, IL-1, IL-6 correlate with the severity of pancreatitis.Neuroendocrine pathways, such as the sympathetic nervous system or parasympathetic nervous system, in turn, have some impact on the immune systems, through a-2 adrenoreceptor stimulation or the cholinergic anti-inflammatory pathway. The investigators aim to use Dexmedetomidine Hydrochloride to decrease the activity of sympathetic nervous system, thus relieve inflammation response.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients diagnosed with severe acute pancreatitis within 48h

• APACHE II≥8

• Patients or the family agreed to receive the treatment, and signed the informed consents

Exclusion Criteria:

• Patients were allergy to the drug

• Patients were diagnosed with Arrhythmia

• Patients with artificial permanent pacemaker implantation